Shares of Bayer surged as much as 6.3% on November 3 after the German conglomerate posted third-quarter results that beat analyst expectations and raised its full-year outlook — a rare bright spot on a day when broader European markets stumbled. The pharmaceuticals division was the standout performer, with sales growing 8% to €4.68 billion and divisional EBITDA jumping 23.6%, fueled by continued strong momentum from cancer drug Nubeqa and kidney-heart medicine Kerendia. The question for investors: Is this a genuine inflection point, or a sugar rush from two products masking deeper vulnerabilities?
• Drug Sales Are Finally Carrying the Company
Third-quarter group sales rose 4.1% to €10.05 billion, beating the €9.92 billion consensus.
Core EBITDA of €1.62 billion came in roughly 13% ahead of analysts' expectations.
Bayer raised its full-year pharma EBITDA margin forecast to 25%–27%, up from 23%–25% — a meaningful upgrade that signals drug profitability is improving, not just revenue. Management has previously outlined plans to push pharma margins toward 30% by 2030 , and this quarter suggests that trajectory is credible.
• Cash Flow Is Improving, but Still Negative
Bayer raised its 2026 free cash flow forecast by €1 billion to a range of negative €1.5 billion to negative €0.5 billion. That's progress — burning less cash — but "less negative" isn't the same as generating money. Settlement payments from ongoing litigation still keep free cash flow below zero , meaning shareholders are effectively subsidizing legal exposure from the 2018 Monsanto acquisition.
• The Crop Science Division Missed Badly
Crop science delivered just €101 million of adjusted earnings versus €164 million expected, which Bayer blamed on higher selling costs and weaker demand in Europe and Asia Pacific. Pharma carried the quarter; agriculture dragged. Any sustainable rally needs both engines firing.
• Debt Remains the Elephant in the Room
Bayer cut its year-end net debt forecast by €1 billion to €28–29 billion.
The company has been weighed down by heavy debt since its $63 billion acquisition of Monsanto in 2018 , and at current levels, interest costs consume a significant share of operating profit. How much of the upgraded profit outlook actually reaches shareholders — rather than being eaten up by financing costs — depends on the pace of deleveraging.
CEO Bill Anderson called Q3 "a turning point." The market wants to believe him — but with crop science stumbling and free cash flow still in the red, the turnaround story needs several more chapters before conviction sets in.